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Introduction
American College of Cardiology/American Heart Association guidelines recommend primary percutaneous coronary intervention (PCI) for patients with ST-segment-elevation myocardial infarction presenting ≤12 hours of symptom onset with a first medical contact-to-device time goal of ≤120 minutes.
Pharmacoinvasive strategy where fibrinolysis is followed by immediate transfer to a PCI-capable hospital for either rescue PCI in case of failed fibrinolysis or routine coronary angiography and PCI in case of successful fibrinolysis may be a valid alternative to primary PCI and part of the primary reperfusion in patients with ST-segment-elevation myocardial infarction in whom long PCIrelated delay is anticipated [1] . The aim of our study is to evaluate safety and efficacy of Primary PCI compared to pharmaco-invasive strategy using streptokinase in patients with ST elevation acute myocardial infarction in Gaza.
Methods

Study design
This prospective, randomize, case-control study was conducted on 145 patients with first attack of acute STEMI who had symptoms onset of myocardial Ischemia within 12 h in association with persistent electrocardiographic (ECG) ST elevation and subsequent release of biomarkers of myocardial necrosis. Patients were presents STEMI at the day time between Sun-Thu 7 am-2 pm (not holiday) and patient presents myocardial infarction at night or weekend or holidays who contraindications for streptokinase or cardiogenic shock were randomize to primary
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PCI, and the patients presents STEMI at Nights or Weekends or
Holidays randomize to pharmaco-invasive strategy.
Study populations
The study population was single Center trial derived from al shifa hospital between January 2019 and October 2012. We identified 145 patients (≥18 years) with STEMI (<12 hours) eligible for either pharmaco-invasive strategy or Primary PCI. All subjects received acetylsalicylic acid, clopidogrel, unfractionated heparin and high dose statin (Atorvastatin 80 mg) according to our guidelines. Patients were excluded from the study if their age was < 18 years or if they have contraindications of fibrinolytic therapy, or multi-vessel coronary artery disease not suitable for revascularization. 
Clinical definitions
End points
Efficacy (primary) endpoint: total death, shock or heart failure at 30 days after myocardial infarction. Secondary (safety) endpoint:
Major Bleeding, minor bleeding or failed streptokinase required emergent PCI.
Statistical analysis
Data was analyzed by SPSS version 19. Continuous variables
were presented as mean± standard deviation (SD) and categorical variables as absolute numbers and percentages. Comparison of demographic and clinical data among the groups was performed using independent t-test for continuous variables and chi-square (χ2) for categorical variables. Pearson's correlation coefficients were calculated to illustrate certain relationships. P values < 0.05 were considered significant. 
Type of intervention
Culprit lesion
PCI was performed only to the culprit artery. The culprit artery was LAD in 75 patients (51.7% of total study population), LCX in 22 (15%) patients, RCA in 42 (28%) patients, OM branch in 6 (4 %) patients and diagonal branch in 2 (1.3%) patient diagonal branch
Door to needle and door to balloon time
In pharmaco-invasive strategy: Average time from medical contact to streptokinase administration was 33.17±15 min. in patient with successful streptokinase all Coronary angiography was performed with 24 hrs., with average time 16 hrs., but in patient with failed streptokinase emergency angiography was required in 39.5% of the patients the median time 6 hours after randomization.
In primary PCI strategy: a 54% of the patients the Door to balloon time was < 20 min. The Door to balloon time was 75.25±20 min, and the Door to balloon was performed in 81% in the time < 90 min.
Endpoints
Primary endpoint: The primary endpoint in primary PCI (17%) and in pharmaco-invasive PCI (16.1%) p = 0.24. There was no difference in 30-day mortality (4.7 % in primary PCI and 4.9% in Pharmacoinvasive strategy (P=0.94) Secondary endpoints:
Emergency angiography was required in 39.5% of the patients in the pharmaco-invasive strategy and the median time for underwent angiography was 6 hours after randomization. TIMI major bleeding occurred among 4 patients (4.9 %) in the Pharmacoinvasive group and in 2 patients (3.1%) of the primary PCI group (P = 0.59). The
Pharmacoinvasive group had 1.9 times the odds of having TIMI major bleed compared with the primary PCI group (Table 2) . 
Subgroup Analysis
In the Pharmacoinvasive group, 32 patients did receive coronary angiography within 6 hours and 57 patients was receive coronary angiography within 24 hours of presentation; 5 underwent angiography later during the index hospitalization and 3 were treated medically (two patients ecstatic coronary arteries and slow flow another patient was nonsignificant stenosis). Three patients died within 48 h of presentation, and 1 patient died later on due to subacute stent thrombosis.
In the primary PCI group, 1 patient died just before reaching the catheterization laboratory, Cardiopulmonary resuscitation and primary PCI was done but patient died in the 
Discussion
In our trial, we report on the efficacy and safety of a
Pharmacoinvasive strategy compared with a primary PCI strategy in Gaza, we found that:
1. First, Streptokinase: It is a very widely used fibrinolytic agent and only available fibrinolytic agent in Gaza, because of its easy availability and low cost. 
2.
Second, Actually, it has to be considered that patients enrolled in our trial were at low risk with a 30-day mortality of 4.8%.
3.
Third, the rate of composite end points (total mortality, shock and heart failure) was similar in two groups.
4.
Forth, a 39.5% of patients in the thrombolysis arm required urgent coronary angiography.
5.
Fifth, major bleeding was slightly lower with a primary
PCI strategy
Our primary endpoints was similar with The STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial compared fibrinolysis followed by PCI within 6 to 24 h to primary PCI. The investigators found that there was no difference in the composite endpoint of death, shock, congestive heart failure, or reinfarction at 30 days between the 2 treatments [2] However, a fibrinolysis-based therapy was associated with slightly higher rates of intracranial hemorrhage, a trend that was not observed after protocol amendment to reduce TNK by 50% for patients > 75 years of age, in our trial we use streptokinase and number of patients who had age > 75 years only 8 patients and 5 of them was randomize to primary PCI strategy [3] . Within this regional STEMI system, > 50% of the patients managed with a Pharmacoinvasive strategy underwent In a large meta-analysis of 7 trials and 2,961 patients, early PCI after fibrinolysis has been found to be associated with a reduced risk of the combined endpoint of death and reinfarction without a significant increase in the risk of major bleeding or stroke [9]. The our result is similar to the STEPP-AMI, trial which a prospective, observational, multicentric study evaluated the efficacy and safety of a strategy of pharmaco-invasive therapy with primary PCI. In this study, tenecteplase was given as the lytic agent followed by catheterization (pharmaco-invasive strategy) within 3-24 hours with timely coronary intervention as appropriate versus standard primary PCI in 200 patients with acute myocardial infarction within 12 hours of symptom onset. The primary endpoint of 30day incidence of death, cardiogenic shock, reinfarction, repeat revascularization, and congestive heart failure, was similar in both groups, although there was a trend toward benefit in the primary PCI group (11.1% vs. 3.9%, p = 0.07). At the end of 2-year followup, the initial benefit from primary PCI seemed to be narrowed as more events have occurred in the primary PCI group vs pharmaco-invasive group (17.8% vs. 13.6%, p = 0.47) [10] Limitations The limitations in this study were the small sample size, short term 30 days of follow-up.
Conclusion
In this randomized trial, early presenting STEMI patients unable to undergo primary PCI within 1 hour (median, 75±20 minutes) were randomized to primary PCI or a pharmaco-invasive strategy with streptokinase followed by PCI. At 1-month followup, there was no statistical difference in all-cause mortality, heart failure or shock. This study suggests that, if primary PCI cannot be performed within 1 hour of presentation, a pharmaco-invasive strategy may be as good as primary PCI.
